Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis...

por van Ruiten, Charlotte C., van der Aart‐van der Beek, Annemarie B, IJzerman, Richard G., Nieuwdorp, Max, Hoogenberg, Klaas, van Raalte, Daniël H, Heerspink, Hiddo J. L.
Publicado 2021

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials

por van der Aart ‐ van der Beek, Annemarie B., van Raalte, Daniel H., Guja, Cristian, Hoogenberg, Klaas, Suchower, Lisa J., Hardy, Elise, Sjöström, C. David, Heerspink, Hiddo J.L.
Publicado 2020

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial

por van der Aart‐van der Beek, Annemarie B., Clegg, Lindsay E., Penland, Robert C., Boulton, David W., Sjöström, C. David, Mentz, Robert J., Holman, Rury R., Heerspink, Hiddo J. L.
Publicado 2020

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials

por van der Aart‐van der Beek, Annemarie B., Cherney, David, Laverman, Gozewijn D., Stefansson, Bergur, van Raalte, Daniel H., Hoogenberg, Klaas, Reyner, Daniel, Li, Qiang, Di Tanna, Gian Luca, Greasley, Peter J., Heerspink, Hiddo J. L.
Publicado 2021

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

por van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C. J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z. I., Heerspink, Hiddo J. L.
Publicado 2021